Chemoprotection refers to the protection from the toxicity of one chemical by the intervention of another. Conflicting preclinical and clinical reports make it difficult to either ignore or accept the use of chemoprotectants during cancer chemotherapy or radiotherapy. The selection of anticancer drugs depends on the type and stage of cancer development. However, very little attention has been paid to the selection of chemoprotectants. The answer to the use of chemoprotectants during cancer therapy lies in their appropriate selection in a case-specific and/or issue-specific manner. The need of the hour is to find better answers on the rationality of chemoprotectants selection during cancer therapy using cutting-edge science. In this commentary, we have presented few examples to justify our view-points.
The last decade has seen significant progress in the field of chemoprotection research. [1] [2] [3] [4] [5] [6] Chemoprotection is defined as the protection from the toxicity of 1 chemical by the administration of another. However, the basic objective of chemoprotection is the intervention with antioxidants and/ or food supplements to protect healthy tissues from the toxic effects of radiation, anticancer drugs, or carcinogens present in the environment. Dietary intervention with bioactive compounds is reported to have promising effects in chemoprotection. 7 However, the strategy becomes jeopardized when it comes to using chemoprotectants during cancer therapy to reduce the unwanted side effects of the drug. Conflicting preclinical and clinical reports make it difficult to either ignore or accept the use of chemoprotectants during cancer chemotherapy and radiotherapy in an unequivocal manner (Table 1 [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] ).
One of the fundamental principles of chemoprotection in cancer therapy is to reduce the unwanted side effects of the drug under trial without affecting the efficacy. This provides the space to discuss the use of chemoprotectants in cancer therapy. A number of reports oppose the use of antioxidants and dietary supplements during active treatment on the grounds of compromise with the efficacy of the drug and clinical outcomes. 26, 27 In contrast, several reports propose the inclusion of chemoprotectants during cancer therapy as they improve the quality of life, increase drug tolerability, and reduce adverse side effects. Interestingly, in some cases, synergistic effects have also been observed. [28] [29] [30] [31] [32] In addition to this, chemoprotectants permit uninterrupted treatment schedules and eliminate the need to reduce drug doses. However, the practical possibility of reduction in drug efficacy cannot be overlooked as the mode of action for many chemotherapeutic agents involves free-radical generation. 33 Bearing in mind the proven beneficial effects of chemoprotectants and also that they could compromise the efficacy of therapeutic drugs, we believe that intervention with chemoprotectants in a case-specific manner with proper consideration such as candidate selection, dose determination, and regimen of administration as well as metabolism can prove to be beneficial.
The majority of antineoplastic drugs are cytotoxic in nature, but precise mechanisms of efficacy and toxicity vary. The selection of anticancer drugs and intensity as well as the duration of treatment depend on the type and stage of cancer development. However, very little attention has been paid to the selection of chemoprotectants. Chemoprotectants also Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug vary from each other in terms of pharmacokinetics, potency, selective accumulation, and molecular mechanism of action, and therefore, the careful consideration of these variables would be of vital importance in the selection of chemoprotectants for subsequent clinical use. Certainly, it is not possible to have a universal chemoprotectant that can help in nullifying the unwanted effects irrespective of the therapeutic measure (drug or radiation). The difficulty lies in how exactly chemoprotectants should be selected and used against anticancer measures without compromising their efficacy.
The answer to this question lies in the search for a strategy to use these agents in a clinical case-specific and/or patient issue-specific manner. Here, we present a few examples to clarify our view.
Streptozotocin (STZ) is a potent growth inhibitor
and alkylating agent used in the treatment of colorectal, pancreatic, adrenocortical, and gastrointestinal cancers. 34 It has also been used for the treatment of Hodgkin's disease. 35 However, its clinical use is restricted on account of its severe cytotoxicity to the pancreatic b-cells. Owing to the presence of a sugar moiety in its structure, STZ exhibits structural resemblance to d-glucose.
It enters b-cells through a glucose transporter GLUT2. The pancreatic b-cells are highly susceptible to STZ-induced toxicity because of their weak antioxidant reserve. 36 If the aim of the treatment is to use STZ against colorectal, adrenocortical, or gastrointestinal cancers, then, simultaneous administration of a high dose of d-glucose along with STZ can competitively inhibit the entry of STZ into the b-cells 37 and, thereby, minimize the ultimate damage. 2. Cyclophosphamide is one of the most widely used drugs for the treatment of different cancers as well as in combination chemotherapy. The therapeutic effect of cyclophosphamide is mainly mediated through its active metabolite phosphoramide mustard through alkylation, whereas acrolein produces unwanted toxic effects. Acrolein, a therapeutically inactive component of cyclophosphamide, induces intracellular reactive oxygen species (ROS) and nitric oxide, which accounts for the major toxicity of the drug. 38 These reactive oxygen and nitrogen species damage cellular lipids, proteins, and DNA, leading to cell death. 39 Hence, a chemoprotectant that can selectively neutralize ROS and is suitable in the context of pharmacokinetics and target organ toxicity of cyclophosphamide can be of clinical importance. It has been well reported that a-lipoic acid effectively protects acrolein-induced toxicity in IMR-90 (a human lung fibroblast cell line) in vitro. 40 Furthermore, Tanel and Averill-Bates 41 demonstrated that N-acetyl cysteine successfully protects the acrolein-induced apoptosis in Chinese hamster ovary cells in vitro. 3. Quercetin is a flavanoid widely used as a dietary supplement. It is reported to have protective effects against several cytotoxic drugs. However, at higher doses it acts as a pro-oxidant because of the generation of reactive metabolites. Scambia et al 42 reported inhibition of primary ovarian and endometrial cancers by quercetin. Furthermore, quercetin treatment along with cisplatin led to reduction in the tumor size to a greater extent than cisplatin alone. 31 These reports indicate the synergistic effects of antioxidant/ dietary supplements on cancer therapy. 4. Amifostine is an organic thiosulfate derivative of cysteamine. It is used with anticancer drugs such as cyclophosphamide and cisplatin, whose cytotoxicity is mainly through free-radical generation. 43 Extensive preclinical and clinical studies have demonstrated that amifostine provides selective protection to normal tissue without compromising the efficacy of the drug being used for treatment. The selective protection of normal cells, compared with tumor cells, can be explained by the much higher concentration of alkaline phosphatase in normal tissues and by the neutral pH, relative to the acidic pH in tumor cells. 44 A recent metaanalysis of 14 randomized clinical trials indicates that without compromising the efficacy, amifostine treatment significantly ameliorates several side effects such as mucositis, esophagaitis, acute xerostomia, dysphagia, acute pnemonitis, and cystitis during cancer radiotherapy. 45 
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In an experimental study, Neuwelt et al 46 showed chemoprotection with N-acetyl-L-cysteine and sodium thiosulfate against melphalan, carboplatin, and etoposide phosphate in brain tumors without compromising efficacy. The anticancer drugs were administered by the intra-arterial route with osmotic blood-brain barrier disruptors, whereas the antioxidant intervention schedule was designed in such a way that the antioxidants remained in the peripheral circulation. Interactions between antioxidant/dietary supplements and antitumor drugs that would reduce the efficacy of the drugs were avoided by temporal and spatial separation of chemoprotectants and chemotherapy. This exemplifies the beneficial effect of a rationale that aids in chemoprotection without compromising the efficacy.
ROS manipulation strategies are an important paradox in the rationale of cancer treatment. These strategies need individual selection of agents as well as development of "redox signaling signatures" for the prediction of efficacy and sys-temic toxicity. 47 The latest opinion reinforces the idea that chemoprotection should not be limited only to interventions in oxidant-antioxidant approaches; rather, chemoprotection should be extended to basic nutritional supplementation. 48 Chemoprotectants should not be looked on as mere blocking agents against the adverse effects of chemotherapeutic agents. Rather, new strategies have to be adopted in parallel with preventive oncology to confer protection to vulnerable tissues while sensitizing malignant ones. 49, 50 The future of chemoprotection lies in the extensive mechanistic evaluation of different chemoprotectants to understand their target-organ-specific molecular mechanisms of action in order to design rational treatment protocols. Furthermore, chemoprevention studies should be extended to understand the basic mechanisms such as xenobiotic activation, detoxification, decreased DNA binding of carcinogens, inhibition of oxidative DNA damage, alteration of cell signaling and malignant transformation, and inhibition of cell invasiveness and metastasis. Careful monitoring of drug-and radiationassociated toxicities can help in designing the protocol for antioxidant/dietary supplement intervention in a case-and situation-specific manner.
Recent unprecedented progress in the field of molecular biology has led to a new subdiscipline of toxicologytoxicogenomics. 51 The knowledge of metabolomics and toxicogenomics should be applied to study the metabolism of different chemotherapeutic drugs as well as the gene activity and the production of specific proteins. Recent reports indicate that genomic biomarkers can be successfully used to evaluate the toxicity of several classical drugs in the major target organs like liver, kidney, and lung. [52] [53] [54] Gene expression profiling can be used as a sensitive biomarker to address specific issues in toxicological evaluation, where classical toxicity evaluation has several limitations. 55 Furthermore, measurement of gene expression at the transcript and protein levels can provide much better information and technical capabilities to predict drug toxicity and adverse drug reactions. 56 Once validated, this can provide a massive amount of information and virtually bring about the possibility of a future where cancer treatment and simultaneous chemoprotection will be carried out taking into account drug and antioxidant/dietary-supplement selection in addition to the type and stage of cancer progression.
However, this confers an additional responsibility on the scientific community to help patients undergoing cancer treatment and suffering from their side effects and to decrease the time gap between the present and the envisaged futures. It has already been emphasized that the application of appropriate chemoprotectants, in isolation as well as in combination with proper dose calibration, might be of great value in the individualization of chemotherapy. 57 Furthermore, Frei 58 has accentuated that it is pivotal for ongoing future clinical trials to assess antioxidant levels and oxidative stress before and after antioxidant supplementation. The use of proteomic techniques can make a substantial contribution to basic research as well as to regulatory toxicology. 59 These technologies might help develop specific drugs for the treatment of cancer and could better facilitate the evaluation of the most effective treatment/dose with already available drugs. It is high time to extend this approach beyond toxicology and to use the "omics"-based biomarker approaches to design different chemoprotection strategies. If issues regarding the use of chemoprotectants during cancer therapy are presently not clear, the chances of risk/benefit should not be left to the part of the patient; rather, scientists should take greater responsibility to find better answers using cutting-edge science.
